Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish. [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
For instance, on April 5, Merck (NYSE: MRK) spent $208 million to acquire a business called Abceutics, which is developing a technology to nullify the effects of certain medicines that Merck is heavily invested in producing. Buying Abceutics is bullish for Merck, because in this context, stopping the drugs from working is a key capability that'll help to differentiate any future products from the competition. Here's why. Controllable therapies will have an advantage on the market To fully appreciate why Merck's purchase of Abceutics is a positive sign for the stock, it's necessary to understand what Abceutics actually offers for its pipeline, which requires a quick discussion of the relevant science. As you may know, antibody-drug conjugates (ADCs) are a very popular area of oncology drug research and development (R&D) right now, and many big pharma companies are trying their hands with them. In an ADC, the engineered antibody behaves as a homing missile or loitering munition
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Global Active Pharmaceutical Ingredients Market Analysis Report 2024-2030: Synthetic API Segment Dominated the Market with the Largest Revenue Share of 70.6% in 2023 [Yahoo! Finance]Yahoo! Finance
- Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults [Yahoo! Finance]Yahoo! Finance
- Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsBusiness Wire
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review 2024: G7 & E7 Regional Insights, Phase, Trial Status, End-points Status and Sponsor Type [Yahoo! Finance]Yahoo! Finance
- A Billion-Dollar Hack Puts UnitedHealth's Empire Under the Microscope [BNN Bloomberg (Canada)]BNN Bloomberg
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website